REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan Capital

REGENXBIO (NASDAQ:RGNX)‘s stock had its “buy” rating restated by equities researchers at Chardan Capital in a report released on Thursday,Benzinga reports. They currently have a $52.00 price target on the biotechnology company’s stock.

Other analysts also recently issued reports about the company. The Goldman Sachs Group downgraded REGENXBIO from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $38.00 to $14.00 in a research note on Tuesday, February 11th. Morgan Stanley increased their target price on REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, March 14th. Raymond James initiated coverage on REGENXBIO in a research note on Friday, February 7th. They set an “outperform” rating and a $27.00 target price for the company. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $30.00 price target on shares of REGENXBIO in a report on Tuesday, January 21st. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, REGENXBIO currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.88.

REGENXBIO Stock Down 1.4 %

RGNX opened at $8.24 on Thursday. The business has a 50 day moving average price of $7.30 and a two-hundred day moving average price of $8.90. The company has a market cap of $408.25 million, a PE ratio of -1.64 and a beta of 1.35. REGENXBIO has a 52 week low of $5.62 and a 52 week high of $22.84.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.26. The firm had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. As a group, sell-side analysts expect that REGENXBIO will post -4.84 EPS for the current fiscal year.

Institutional Investors Weigh In On REGENXBIO

A number of large investors have recently bought and sold shares of RGNX. GAMMA Investing LLC grew its holdings in REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 2,510 shares during the last quarter. FMR LLC grew its holdings in REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,656 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in REGENXBIO during the 4th quarter valued at $54,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of REGENXBIO in the fourth quarter valued at $79,000. Finally, Laurion Capital Management LP purchased a new stake in shares of REGENXBIO in the fourth quarter valued at $79,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.